Inhibition of NF-κB signaling as a strategy in disease therapy

Current Topics in Microbiology and Immunology

Volumn 349, Issue , 2011, Pages 245-263

  Gilmore, Thomas D ^a   Garbati, Michael R ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APILIMOD; BARDOXOLONE METHYL; BORTEZOMIB; CURCUMIN; DOXORUBICIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGONUCLEOTIDE; PROTEIN INHIBITOR; TACROLIMUS; TRANSCRIPTION FACTOR REL; DNA;

ARTICLE; ATOPIC DERMATITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL TRANSPORT; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ECZEMA; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSORIASIS; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSACTIVATION; TREATMENT PLANNING; ACTIVE TRANSPORT; ANIMAL; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY; REVIEW;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; DNA; HUMANS; I-KAPPA B KINASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MULTIPLE MYELOMA; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84859946812     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82-2010-105     Document Type: Article

References (95)

1. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417-421 (Pubitemid 38610244)
2. Agou F, Courtois G, Chiaravalli J, Baleux F, Coïc YM, Traincard F, Israël A, Véron M (2004) Inhibition of NF-κB activation by peptides targeting NF-κB essential modulator (NEMO) oligomerization. J Biol Chem 279:54248-54257 (Pubitemid 40053162)
3. Arkan MC, Greten FR (2010) IKK and NF-κB mediated functions in carcinogenesis. Current topics in microbiology and immunology. Springer, Berlin (this issue)
4. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM (1998) The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation. Brain Res Mol Brain Res 57:63-72 (Pubitemid 28279561)
5. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112
6. Bassères D, Baldwin AS (2006) Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830 (Pubitemid 44657854)
7. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H (2002) Identification of signal transduction pathways involved in constitutive activation in breast cancer cells. Oncogene 21:2066-2078 (Pubitemid 34270895)
8. Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE, Lenz G, Anderson DE, Arnoult D, Vazquez A, Sakai K, Zhang J, Meng Z, Veenstra TD, Staudt LM, Lenardo MJ (2009) Casein kinase 1α governs antigen-receptor- induced NF-κB activation and human lymphoma cell survival. Nature 458:92-96
9. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129:1065-1079 (Pubitemid 46891036)
10. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC (2003) BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 278:1450-1456 (Pubitemid 36801370)
11. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP (2000) Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105:1799-1806 (Pubitemid 30421761)
12. Clark K, Plater L, Peggie M, Cohen P (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IκB kinase ε: a distinct kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 284:14136-14146
13. Clément JF, Meloche S, Servant MJ (2008) The IKK-related kinase: from innate immunity to oncogenesis. Cell Res 18:889-899
14. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R, Pasqualucci L (2009) Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 459:717-721
15. Courtois G, Gilmore TD (2006) Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 25:6831-6843 (Pubitemid 44657855)
16. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 61:3535-3540 (Pubitemid 32694955)
17. Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874 (Pubitemid 34028664)
18. Davis RE, Zhang YQ, Southall N, Staudt LM, Austin CP, Inglese J, Auld DS (2007) A cell-based assay for IκBβ stabilization using a two-color dual luciferase-based sensor. Assay Drug Dev Technol 5:85-103 (Pubitemid 46581243)
19. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 463:88-92
20. De Bosscher K, Vanden Berge W, Haegeman G (2006) Cross-talk between nuclear receptors and nuclear factor κB. Oncogene 25:6868-6886
21. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076
22. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE (2005) Inducible IκB kinase/IκB kinase ε expression is induced by CK2 and promotes aberrant nuclear factor-κB activation in breast cancer cells. Cancer Res 65:11375-11383 (Pubitemid 41823949)
23. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL (2009) Targeting the NF-κB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 121:1-13
24. Ehrlich LC, Hu S, Peterson PK, Chao CC (1998) IL-10 down-regulates human microglial IL-8 by inhibition of NF-κB activation. Neuroreport 9:1723-1726 (Pubitemid 28289174)
25. Eyre S, Hinks A, Flynn E, Martin P, Wilson AG, Maxwell JR, Morgan AW, Emery P, Steer S, Hocking LJ, Reid DM, Harrison P, Wordsworth P, Thomson W, Worthington J, Barton A (2010) Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Ann Rheum Dis 69:1407-1408
26. Fagerlund R, Melén K, Cao X, Julkunen I (2008) NF-kB p52, RelB and c-Rel are transported into the nucleus via a subset of importin alpha molecules. Cell Signal 20:1442-1451
27. Fan Y, Dutta J, Gupta N, Fan G, Gélinas C (2008) Regulation of programmed cell death by NF-κB and its role in tumorigenesis and therapy. Adv Exp Med Biol 615:223-250
28. Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273:8545-8548 (Pubitemid 28176125)
29. Folmer F, Jaspars DM, Diederich M (2008) Marine natural products as targeted modulators of the transcription factor NF-κB. Biochem Pharmacol 75:603-617
30. Garber K (2009) Ariad's NFκB patent claims shot down on appeal. Nat Biotechnol 27:494-495
31. García-Piñeres AJ, Lindenmeyer MT, Merfort I (2004) Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potential. Life Sci 75:841-856 (Pubitemid 38737421)
32. Gilmore TD (2007) Multiple myeloma: lusting for NF-κB. Cancer Cell 12:95-97
33. Gilmore TD, Herscovitch M (2006) Inhibitors of NF-κB signaling:785 and counting. Oncogene 25:6887-6899
34. Gilmore TD, Kalaitzidis D, Liang M-C, Starczynowski DT (2004) The c-Rel transcription factor and B-cell proliferation: a deal with the devel. Oncogene 23:2275-2286 (Pubitemid 38496782)
35. Godl K, Gruss OJ, Eickhoff J, Wissing J, Blencke S, Weber M, Degen H, Brehmer D, Õrfi L, Horváth Z, Kéri G, Müller S, Cotton M, Ullrich A, Daub H (2005) Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 65:6919-6926 (Pubitemid 41060731)
36. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, Seldin MF, Criswell LA, Plenge RM, Holers VM, Mikuls TR, Sokka T, Moreland LW, Bridges Jr SL, Xie G, Begovich AB, Siminovitch KA (2009) REL, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 41:820-823
37. Grisham MB, Palombella VJ, Elliott PJ, Conner EM, Brand S, Wong HL, Pien C, Mazzola LM, Destree A, Parent L, Adams J (1999) Inhibition of NF-κB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol 300:345-363 (Pubitemid 28500610)
38. Guo G, Wang T, Gao Q, Tamae D, Wong P, Chen T, Chen WC, Shively JE, Wong JY, Li JJ (2004) Expression of ErbB2 enhances radiation-induced NF-κB activation. Oncogene 23:535-545 (Pubitemid 38175008)
39. Hayden MS, Ghosh S (2008) Shared principles in NF-κB signaling. Cell 132:344-362
40. Hayes CJ, Sherlock AE, Selby MD (2006) Enantioselective total syntheses of (-)-clastolactacystin β-lactone and 7-epi-(-)-clasto-lactacystin β-lactone. Org Biomol Chem 4:193-195
41. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647 (Pubitemid 34967682)
42. Hiscott J, Nguyen T-LA, Arguello M, Nakhaei P, Paz S (2006) Manipulation of the nuclear factor-κB pathway and the innate immune response by viruses. Oncogene 25:6844-6867 (Pubitemid 44657856)
43. Jagannath S, Kyle RA, Palumbo A, Siegel DS, Cunningham S, Berenson J (2010) The current status and future of multiple myeloma in the clinic. Clin Lymphoma Myeloma 10:E1-E16
44. Jobin C, Hellerbrand C, Licato LL, Brenner DA, Sartor RB (1998) Mediation by NF-κB of cytokine induced expression of intercellular adhesion molecule 1 (ICAM-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut 42:779-787 (Pubitemid 28277216)
45. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 16:46-52 (Pubitemid 40270849)
46. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M (2000) Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase. J Biol Chem 275:36062-36066
47. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26 (Pubitemid 38088695)
48. Keino H, Watanabe T, Sato Y, Niikura M, Wada Y, Okada A (2008) Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther 10:R122
49. Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A, Aggarwal BB (2007) Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 7:344-351 (Pubitemid 46731200)
50. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM (2001) The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem Biol 8:759-766 (Pubitemid 32752455)
51. Lai C, Jiang X, Li X (2006) Development of luciferase reporter-based cell assays. Assay Drug Dev Technol 4:307-315 (Pubitemid 44083585)
52. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM (2005) Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40 (Pubitemid 40075775)
53. Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM (2008) Compensatory IKKα activation of classical NF-κB signaling during IKKβ inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci USA 105:20798-20803
54. Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG (2009) Novel therapies in the treatment of multiple myeloma. Nat Rev Clin Oncol 6:596-603
55. Lee DF, Hung MC (2008) Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 14:5656-5662
56. Lentsch AB, Shanley TP, Sarma V, Ward PA (1997) In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J Clin Invest 100:2443-2448 (Pubitemid 27514883)
57. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Müller-Hermelink H-K, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smelan EB, Fisher RI, Chan WC, Staudt LM (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679 (Pubitemid 351432507)
58. Letoha T, Somlai C, Takacs T, Szabolcs A, Jarmay K, Rakonczay Z Jr, Hegyi P, Varga I, Kaszaki J, Krizbai I, Boros I, Duda E, Kusz E, Penke B (2005) A nuclear import inhibitory peptide ameliorates the severity of cholecystokinin-induced acute pancreatitis. World J Gasteroenterol 11:990-999 (Pubitemid 40347751)
59. Liang M-C, Bardhan S, Li C, Pace EA, Porco JA Jr, Gilmore TD (2003) Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase. Mol Pharmacol 64:123-131 (Pubitemid 36759824)
60. Liang M-C, Bardhan S, Pace EA, Rosman D, Beutler JA, Porco JA Jr, Gilmore TD (2006) Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity. Biochem Pharmacol 71:634-645 (Pubitemid 43121997)
61. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J (1995) Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270:14255-14258
62. Luedde T, Bereza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M (2007) Deletion of NEMO/IKKγ in liver parenchymal cells causes steatoheptatis and hepatocellular carincoma. Cancer Cell 11:119-132 (Pubitemid 46209851)
63. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78:773-785 (Pubitemid 24294453)
64. Pande V, Sousa SF, Ramos MJ (2009) Direct covalent modification as a strategy to inhibit nuclear factor-κB. Curr Med Chem 16:4261-4273
65. Park SJ, Lee MY, Bon BS, Youn HS (2009) TBK1-targeted suppression of TRIF-dependent signaling pathway of Toll-like receptors by 6-shogaol, an active component of ginger. Biosci Biotechnol Biochem 73:1474-1478
66. Pasparakis M (2009) Regulation of tissue homeostasis by NF-κB signaling: implications for inflammatory diseases. Nat Rev Immunol 9:778-788
67. Perkins ND (2006) Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 25:6717-6730 (Pubitemid 44657848)
68. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE (2001) Her-1/Neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299 (Pubitemid 32269934)
69. Ríos JL, Recio MC, Escandell JM, Andújar I (2009) Inhibition of transcription factors by plantderived compounds and their implications in inflammation and cancer. Curr Pharm Des 15:1212-1237
70. Sakurai T, Maeda S, Chang L, Karin M (2006) Loss of hepatic NF-κB activity enhances chemical carcionogenesis through sustained c-Jun. N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103:10544-10551 (Pubitemid 44078014)
71. Scheidereit C (2006) IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 25:6685-6705 (Pubitemid 44657846)
72. Sen J, Venkataraman L, Shinkai Y, Pierce JW, Alt FW, Burakoff SJ, Sen R (1995) Expression and induction of nuclear factor-κB-related proteins in thymocytes. J Immunol 154:3213-3221
73. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB (2006) A synthetic triterpenoid, CDDO-Me, inhibits IκBα kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor κB-regulated gene products in human leukemic cells. Clin Cancer Res 12:1828-1838
74. Skaug B, Jiang X, Chen ZJ (2009) The role of ubiquitin in NF-κB regulatory pathways. Annu Rev Biochem 78:769-796
75. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 97:4844-4849 (Pubitemid 30238645)
76. Strickland I, Ghosh S (2006) Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 65(Suppl 3):iii75-iii82 (Pubitemid 44629109)
77. Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA (2010) A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res 16:348-357
78. Sun S-C, Cesarman E (2010) NF-κB as a target for oncogenic viruses. In: Current topics in microbiology and immunology. Springer, Berlin (this issue)
79. Swinney DC, Xu Y-Z, Scarafia LE, Lee I, Mak AY, Gan Q-F, Ramesha CS, Mulkins MA, Dunn J, So O-Y, Biegel T, Dinh M, Volkel P, Barnett J, Dalrymple SA, Lee S, Huber M (2002) A small molecule ubiquitination inhibitor blocks NF-κB-dependent cytokine expression in cells and rats. J Biol Chem 277:23573-23581 (Pubitemid 34952193)
80. Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T (2006) Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-κB-independent mechanisms. Anticancer Res 26:1869-1876 (Pubitemid 43989444)
81. Tang W, Li Y, Yu D, Thomas-Tikhonenko A, Spiegelman VS, Fuchs SY (2005) Targeting β-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res 65:1904-1908 (Pubitemid 40478619)
82. Taylor PC, Feldmann (2009) Anti-TNF biologic agents still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 5:578-582
83. Tian W, Liou H-C (2009) RNAi-mediated c-Rel silencing leads to apoptosis of B cell tumor cells and suppresses antigenic immune response in vivo. PLoS ONE 4:e5028
84. Torgerson TR, Colosia AD, Donahue JP, Lin Y-Z, Hawiger J (1998) Regulation of NF-κB, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-κB p50. J Immunol 161:6084-6092 (Pubitemid 28535979)
85. Tran TA, McCoy MK, Sporn MB, Tansey MG (2008) The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection. J Neuroinflammation 5:14
86. Trepicchio WL, Dorner AJ (1998) The therapeutic utility of Interleukin-11 in the treatment of inflammatory disease. Expert Opin Investig Drugs 7:1501-1504 (Pubitemid 28408811)
87. Tsukamoto S, Takeuchi T, Rotinsulu H, Mangindaan RE, van Soest RW, Ukai K, Kobayashi H, Namikoshi M, Ohta T, Yokosawa H (2008) Leucettamol A: a new inhibitor of Ubc13-Uev1A interaction isolatd from a marine sponge, Leucetta aff. microrhaphis. Bioorg Med Chem Lett 18:6319-6320
88. Umezawa K, Chaicharoenpong C (2002) Molecular design and biological activities of NF-κB inhibitors. Mol Cells 14:163-167 (Pubitemid 41594968)
89. Venkataraman L, Burakoff SJ, Sen R (1995) FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med 181:1091-1099
90. Watanabe M, Nakashima M, Togano T, Higashihara M, Watanabe T, Umezawa K, Horie R (2008) Identification of the RelA domain responsible for action of a new NF-κB inhibitor DHMEQ. Biochem Biophys Res Commun 376:310-314
91. Wiestner A, Staudt LM (2003) Towards molecular diagnosis and targeted therapy of lymphoid malignancies. Semin Hematol 40:296-307 (Pubitemid 37296779)
92. Xie Y, Rinderspacher A, Liu Y, Gong G, Smith DH, Wyler M, Brandén L, Deng SX (2009) Small-molecule modulators of the NF-κB pathway newly identified by a translocation-based cellular assay. Curr Top Med Chem 9:1172-1180
93. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurio F, Manning AM, Ciechanover A, Ben-Neriah Y (1997) Inhibition of NF-κB cellular function via specific targeting of the IκB-ubiquitin ligase. EMBO J 16:6486-6494 (Pubitemid 27483274)
94. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10:3207-3215 (Pubitemid 38619702)
95. Zhou H, Monack DM, Kayagaki N, Wertz I, Yin J, Wolf B, Dixit VM (2005) Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-κB activation. J Exp Med 202:1327-1332 (Pubitemid 41668735)